Incyte Genomics (INCY) Misses Q2 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.42 +0.02%
Financial Fact:
Interest expense: -9.48M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Interest expense: -9.48M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Incyte Genomics (NASDAQ: INCY) reported Q2 EPS of ($0.41), $0.05 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $19.17 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $108 at Bernstein SocGen Group
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Choice Hotels (CHH) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
